Latanoprost Fdc International (Latanoprost)

Latanoprost activates prostaglandin F (FP) receptors in the eye, which remodels the extracellular matrix and enhances uveoscleral outflow of aqueous humor. This increased outflow lowers intra‑ocular pressure, addressing the primary cause of glaucoma progression.

The dosing regimen for Latanoprost is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for Latanoprost in pregnancy and lactation are limited. It is classified as pregnancy category unknown, and use is generally reserved for situations where the potential benefit justifies any potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which typically offers once‑daily dosing and strong intra‑ocular pressure reduction. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogs often have a more favorable dosing convenience and comparable efficacy.

Latanoprost eye drops should be stored at room temperature, below 25 °C, in the original packaging. Protect the bottle from moisture and direct sunlight. Do not freeze the product, and keep the tip clean to avoid contamination.

Latanoprost is administered as a sterile ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac. Close the eye gently for a few seconds and avoid blinking excessively.

Serious risks, though rare, include severe anterior uveitis, allergic reactions affecting the eyelid or conjunctiva, significant loss of visual acuity, and ocular infection. Patients should seek immediate medical attention if they experience pain, redness, vision changes, or swelling.

Latanoprost should be avoided in patients with known hypersensitivity to the drug or any of its excipients, those who have had recent ocular surgery, or individuals with active ocular infections. Caution is also advised for patients with corneal endothelial disorders.